FDA OKs Relistor for opioid patients

April 28, 2008

The U.S. Food and Drug Administration has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients receiving opioids.

The FDA said opioids are often prescribed on a continuous basis for patients with late-stage, advanced illness to help alleviate pain, such as in cases of incurable cancer, heart failure and Alzheimer's disease with dementia.

But opioids can interfere with normal bowel movements by relaxing the intestinal smooth muscles and preventing them from contracting and pushing out waste products. Relistor acts by blocking opioid entrance into the cells, thus allowing the bowels to continue to function normally.

"This new drug will be helpful to patients who experience severe constipation associated with the continuous use of morphine or other opioids, which are an important part of care for patients with late-stage, advanced illness." said Dr. Joyce Korvick, deputy director of the FDA's division of gastroenterology products.

Relistor is manufactured by Wyeth Pharmaceuticals Inc. of Philadelphia and Progenics Pharmaceuticals of Tarrytown, N.Y.

Copyright 2008 by United Press International

Explore further: Drug for digestive problem can extend survival for many advanced cancer patients

Related Stories

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.